Long-term Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rate in the Middle East and North Africa: a Systematic Review and Meta-analysis of 178 Population-Based Studies

2021 ◽  
Vol 23 (9) ◽  
Author(s):  
Nami Mohammadian Khonsari ◽  
Ehsan Shahrestanaki ◽  
Hanieh-Sadat Ejtahed ◽  
Shirin Djalalinia ◽  
Ali Sheidaei ◽  
...  
2015 ◽  
Vol 44 (4) ◽  
pp. 232-244 ◽  
Author(s):  
Pouria Heydarpour ◽  
Shayan Khoshkish ◽  
Shabnam Abtahi ◽  
Maziar Moradi-Lakeh ◽  
Mohammad Ali Sahraian

Background: Multiple sclerosis (MS) is one of the most common neurological disorders and a leading cause of nontraumatic disability in young adults in many countries. Recent reports from the Middle East and North Africa have suggested a moderate to high risk of MS in these countries. Methods: A literature search was performed in August 2014 in MEDLINE, EMBASE, and IMEMR to retrieve original population-based studies on MS epidemiology in the Middle East and North African countries published between 1st January 1985 and 1st August 2014. We designed search strategies using the key words: MS, prevalence, incidence, and epidemiology. According to the inclusion criteria, 52 studies were included in this systematic review. Results: McDonald's criteria were the most widely used diagnostic criteria in the studies. Most studies were conducted in single hospital-based centers with a defined catchment area. The female/male ratio ranged from 0.8 in Oman to 4.3 in Saudi Arabia. MS prevalence ranged from 14.77/100,000 population in Kuwait (2000) to 101.4/100,000 in Turkey (2006). The overall MS prevalence in the region was 51.52/100,000. The mean age at disease onset ranged from 25.2 years in Kuwait to 32.5 years in Northeastern Iran, with an overall estimate of 28.54 years. Conclusions: Recent advances in MS registries will allow nation-wide studies and temporal comparisons between countries, provided that age- and sex-standardized estimates are available.


Author(s):  
Abbas Balouchi ◽  
Mojgan Haj Ahmadi Pour Rafsanjani ◽  
Kholoud Al-Mutawaa ◽  
Mahin Naderifar ◽  
Hosein Rafiemanesh ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Jialing Zhang ◽  
Xiangxue Lu ◽  
Jianan Feng ◽  
Han Li ◽  
Shixiang Wang

Introduction. The present meta-analysis was to explore the efficacy of hydroxychloroquine (HCQ) in IgA nephropathy patients in terms of proteinuria. Method. We systematically searched PubMed and Embase for studies that compared HCQ and other treatments to reduce proteinuria in patients with IgA nephropathy up to June 2021. Mean ± SD of percentage change and level of proteinuria was calculated. Results. A total of 5 studies with 587 participants were included. IgA nephropathy patients who received HCQ were at a lower level of mean proteinuria at 6 months. However, there was no statistical difference between HCQ and control group considering percentage reduction in proteinuria. The long-term therapeutic effect of HCQ might be inferior to HCQ and renin-angiotensin-aldosterone system inhibition. Conclusion. HCQ might play a role in the reduction of proteinuria in IgA nephropathy patients. The addition of HCQ to other immunosuppressive agents should be clarified further.


2019 ◽  
Vol 7 (9) ◽  
pp. e1197-e1225 ◽  
Author(s):  
Alex Smolak ◽  
Hiam Chemaitelly ◽  
Joumana G Hermez ◽  
Nicola Low ◽  
Laith J Abu-Raddad

2019 ◽  
Vol 66 (7) ◽  
pp. 701-728 ◽  
Author(s):  
Rami H. Al‐Rifai ◽  
Karima Chaabna ◽  
Thomas Denagamage ◽  
Walid Q. Alali

Food Control ◽  
2020 ◽  
Vol 109 ◽  
pp. 106908
Author(s):  
Rami H. Al-Rifai ◽  
Karima Chaabna ◽  
Thomas Denagamage ◽  
Walid Q. Alali

Sign in / Sign up

Export Citation Format

Share Document